TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with ...
TransCode Therapeutics announces dosing of first two patients in Phase 1 trial for TTX-MC138, an antisense oligonucleotide targeting microRNA-10b to treat metastatic cancer. Several additional patients are being screened for enrollment in the multicenter, open-label study evaluating safety and tolerability.
Related Clinical Trials
Reference News
TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with ...
TransCode Therapeutics announces dosing of first two patients in Phase 1 trial for TTX-MC138, an antisense oligonucleotide targeting microRNA-10b to treat metastatic cancer. Several additional patients are being screened for enrollment in the multicenter, open-label study evaluating safety and tolerability.